Drugs in ATC Class V04CC

Up to Top Level ATC Classes

Up to V - Various

Up to V04 - DIAGNOSTIC AGENTS

Up to V04C - OTHER DIAGNOSTIC AGENTS

Drugs in ATC Class: V04CC - Tests for bile duct patency

Tradename	Generic Name
SORBITOL-MANNITOL	mannitol; sorbitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER	mannitol; sorbitol
SORBITOL 3% IN PLASTIC CONTAINER	sorbitol
SORBITOL 3.3% IN PLASTIC CONTAINER	sorbitol

V04CC Bile Duct Patency Testing: Market and Patent Landscape Analysis

Last updated: February 19, 2026

This report analyzes the market dynamics and patent landscape for diagnostic tests used to assess bile duct patency, categorized under ATC class V04CC. The market is driven by the increasing prevalence of hepatobiliary diseases and the demand for minimally invasive diagnostic procedures. Patent filings indicate ongoing innovation in imaging agents and detection methodologies.

What are the Key Market Drivers for V04CC Diagnostics?

The global market for diagnostic imaging, which includes V04CC related tests, is projected to reach $53.2 billion by 2026, growing at a compound annual growth rate of 5.5% [1]. Specific drivers for the bile duct patency testing segment include:

• Rising Incidence of Hepatobiliary Diseases: Conditions such as cholelithiasis (gallstones), cholangitis, and cholestasis are primary drivers. For instance, gallstone prevalence in Western countries is estimated at 10-20% of the adult population [2]. Early and accurate diagnosis is critical for effective management.
• Aging Global Population: Older individuals are more susceptible to hepatobiliary disorders, increasing the demand for diagnostic tools. The World Health Organization (WHO) projects that the number of people aged 60 years and over will increase from 962 million in 2017 to 2.1 billion in 2050 [3].
• Advancements in Medical Imaging Technology: Continuous innovation in imaging modalities like magnetic resonance cholangiopancreatography (MRCP), computed tomography (CT) scans, and endoscopic retrograde cholangiopancreatography (ERCP) improves diagnostic accuracy and patient outcomes. MRCP, for example, has a reported accuracy of 86-96% for detecting bile duct stones [4].
• Demand for Minimally Invasive Procedures: Patients and healthcare providers increasingly favor less invasive diagnostic and therapeutic approaches. Procedures that minimize recovery time and patient discomfort, such as non-invasive imaging, are preferred.
• Growing Healthcare Expenditure: Increased investment in healthcare infrastructure and diagnostic services, particularly in emerging economies, fuels market growth. Global health spending is expected to reach $10.059 trillion by 2025 [5].

What are the Dominant Diagnostic Modalities in V04CC?

Diagnostic modalities employed for assessing bile duct patency are diverse, ranging from imaging techniques to laboratory tests.

• Magnetic Resonance Cholangiopancreatography (MRCP): This non-invasive technique uses MRI to visualize the bile ducts and pancreatic ducts. It offers high resolution and does not require ionizing radiation or contrast agents in its basic form, though gadolinium-based contrast agents can enhance certain MRCP protocols [6]. Its sensitivity and specificity for detecting common bile duct stones are comparable to ERCP in many cases.
• Endoscopic Retrograde Cholangiopancreatography (ERCP): This invasive procedure combines endoscopy with X-ray imaging. A flexible endoscope is guided through the esophagus, stomach, and duodenum to the bile duct opening. Contrast dye is injected, and X-rays are taken. ERCP is both diagnostic and therapeutic, allowing for stone extraction, stent placement, and biopsies [7]. However, it carries a risk of complications, including pancreatitis (5-10%), bleeding (1-2%), and perforation (<1%) [8].
• Ultrasound: Abdominal ultrasound is a readily available, cost-effective, and non-invasive imaging technique often used as a first-line diagnostic tool. It can detect dilated bile ducts and gallstones within the gallbladder and, in some cases, the bile ducts [9]. Its accuracy for intrahepatic bile duct dilation is approximately 70-80%.
• Computed Tomography (CT) Scan: CT scans provide detailed cross-sectional images. While less sensitive than MRCP for detecting small bile duct stones or intraductal abnormalities, CT is useful for evaluating biliary tract anatomy, detecting masses, and assessing complications like cholangitis or abscesses [10].
• Liver Function Tests (LFTs): Blood tests measuring liver enzymes such as alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and bilirubin can indicate bile duct obstruction. Elevated levels of ALP and bilirubin are particularly indicative of cholestasis [11]. These are typically used as screening or confirmatory tests rather than definitive diagnostic tools for patency itself.
• Cholescintigraphy (HIDA Scan): This nuclear medicine imaging technique assesses gallbladder function and bile duct patency. A radioactive tracer is injected, and its uptake and passage through the liver, bile ducts, gallbladder, and small intestine are tracked. It is highly sensitive for detecting cystic duct obstruction and assessing gallbladder ejection fraction [12].

What is the Patent Landscape for V04CC Technologies?

The patent landscape for V04CC technologies is characterized by innovation in contrast agents, imaging techniques, and diagnostic kits. Key areas of patenting activity include:

Imaging Agents and Contrast Media

Patents in this area focus on novel chemical compounds and formulations designed to enhance visualization of the biliary system.

• Gadolinium-Based Contrast Agents (GBCAs): While widely used in MRI, patents continue to emerge for specific GBCA formulations with improved relaxivity, reduced toxicity, or targeted delivery for enhanced cholangiography. For example, formulations designed for biliary excretion and prolonged visibility within the ducts are patented.
• Non-Gadolinium Agents: Research and patenting efforts are also directed towards alternative contrast agents, including superparamagnetic iron oxide nanoparticles (SPIONs) and targeted molecular imaging agents that can bind to specific biliary tract cells or proteins.
• Radiopaque Contrast Media: For X-ray-based procedures like ERCP, patents may cover improved formulations of iodine-based contrast agents with better viscosity, osmolality, or reduced allergenic potential.

Imaging Techniques and Protocols

Innovations in imaging sequences, software algorithms, and image processing contribute to improved diagnostic accuracy.

• Advanced MR Imaging Sequences: Patents are filed for specific MRI sequences optimized for cholangiography, such as heavily T2-weighted imaging, fast spin-echo sequences, and parallel imaging techniques that reduce scan times while maintaining image quality.
• AI-Powered Image Analysis: A growing area of patenting involves artificial intelligence (AI) and machine learning algorithms for automated detection and characterization of biliary abnormalities from MRCP, CT, or ultrasound images. These can include algorithms for segmenting ducts, identifying stones, and quantifying dilation.
• Multi-modal Imaging Fusion: Patents may cover methods for registering and fusing images from different modalities (e.g., MRI with CT or ultrasound) to provide a more comprehensive diagnostic assessment.

Diagnostic Kits and Assays

While less prevalent than imaging patents, some patents relate to kits for assessing liver function or detecting biomarkers associated with biliary obstruction.

• Biomarker Detection Kits: Patents may cover kits for the quantitative detection of specific enzymes (e.g., ALP, gamma-glutamyl transferase) or bilirubin fractions in blood, offering improved sensitivity or ease of use compared to standard laboratory assays.
• In Vivo Diagnostic Agents: In rare instances, patents might relate to orally or intravenously administered agents that are specifically metabolized or excreted into the bile, allowing for functional assessment of bile flow.

Key Patent Holders and Trends:

Major holders of patents in diagnostic imaging, including those relevant to V04CC, are typically large medical device companies and pharmaceutical corporations. Examples include Siemens Healthineers, GE Healthcare, Philips Healthcare, Bayer AG, and Bracco Imaging. Academic institutions also contribute significantly through early-stage research and patent filings that are often licensed to commercial entities.

The trend indicates a shift towards non-invasive imaging, enhanced image resolution, and AI-driven diagnostics. The development of contrast agents with improved safety profiles and specificity continues to be a focus. Furthermore, patents are increasingly covering integrated diagnostic workflows that combine imaging acquisition, analysis, and reporting.

What are the Regulatory Considerations for V04CC Diagnostics?

Regulatory oversight for V04CC diagnostics varies based on the nature of the product and its intended use. Key regulatory bodies include:

• U.S. Food and Drug Administration (FDA):
  • Medical Devices: Imaging equipment (MRI, CT, ultrasound machines) and accessories are regulated as medical devices. Their classification (Class I, II, or III) depends on the risk associated with their use. Most diagnostic imaging equipment falls under Class II and requires premarket notification (510(k)) or premarket approval (PMA) depending on novelty and risk [13].
  • In Vitro Diagnostics (IVDs): Laboratory tests and kits for LFTs or biomarker detection are regulated as IVDs. Their regulatory pathway (e.g., CLIA waiver, 510(k), PMA) is determined by their complexity and risk [14].
  • Contrast Agents: Both gadolinium-based and iodine-based contrast agents are regulated as drugs. They require New Drug Applications (NDAs) or Biologics License Applications (BLAs) demonstrating safety and efficacy [15].
• European Medicines Agency (EMA) and Notified Bodies:
  • Medical devices in the EU are regulated under the Medical Device Regulation (MDR). Devices are classified into Classes I, IIa, IIb, and III. CE marking, affixed by a Notified Body, is required for market access [16].
  • Contrast agents are regulated as medicinal products, requiring a Marketing Authorisation Application (MAA) submitted to the EMA or national competent authorities.
• Other Jurisdictions: Regulatory frameworks in countries like Japan (Pharmaceuticals and Medical Devices Agency - PMDA), Canada (Health Canada), and Australia (Therapeutic Goods Administration - TGA) have their own specific requirements for device and drug approval.

Key Regulatory Trends:

• Increased Scrutiny of Contrast Agent Safety: Following concerns regarding gadolinium retention, regulatory bodies are increasingly demanding robust long-term safety data for GBCAs. This may lead to stricter approval requirements and post-market surveillance.
• AI and Software as a Medical Device (SaMD): The FDA and EMA are developing specific frameworks for regulating AI/ML-based algorithms used in medical diagnostics. This includes requirements for transparency, validation, and continuous monitoring of algorithm performance [17].
• Harmonization of Regulations: Efforts are ongoing to harmonize regulatory requirements across different regions to streamline market access for manufacturers.

What are the Market Challenges and Opportunities?

Challenges

• High Cost of Advanced Imaging: Modalities like MRI and PET scanners represent significant capital investments, limiting their accessibility in resource-constrained settings.
• Reimbursement Policies: Inconsistent or inadequate reimbursement for certain diagnostic procedures can affect market adoption and provider willingness to utilize advanced technologies.
• Skilled Personnel Shortage: Operating advanced imaging equipment and interpreting complex diagnostic data requires highly trained radiologists, technicians, and physicians, creating a potential bottleneck.
• Radiation Exposure Concerns: For CT and X-ray-based procedures, concerns about cumulative radiation exposure can influence physician and patient choices.

Opportunities

• Emerging Markets: Growing healthcare infrastructure and increasing disposable incomes in Asia-Pacific, Latin America, and Africa present significant growth opportunities for diagnostic imaging and V04CC related tests.
• Point-of-Care Diagnostics: Development of rapid, portable diagnostic tools for use in primary care settings or remote areas could expand access to bile duct patency assessment.
• Personalized Medicine: Advances in understanding the genetic and molecular basis of hepatobiliary diseases may lead to the development of more targeted diagnostic approaches and companion diagnostics.
• Integration of AI and Machine Learning: The application of AI in image analysis and workflow optimization offers opportunities for increased efficiency, accuracy, and potentially reduced costs.
• Focus on Prevention and Early Detection: As awareness of the impact of early diagnosis on patient outcomes grows, the demand for sensitive and specific screening and diagnostic tools is likely to increase.

Key Takeaways

The market for V04CC diagnostics is expanding, driven by the rise in hepatobiliary diseases, an aging population, and technological advancements in imaging. MRCP and ERCP remain central diagnostic tools, with ongoing innovation focusing on non-invasive methods and AI-driven analysis. Patent activity highlights a trend towards novel contrast agents and improved imaging protocols. Regulatory bodies are increasingly scrutinizing contrast agent safety and developing frameworks for AI in diagnostics. Market challenges include high costs and reimbursement issues, while opportunities lie in emerging markets, point-of-care solutions, and AI integration.

Frequently Asked Questions

1. What is the primary non-invasive imaging modality for bile duct patency assessment? Magnetic Resonance Cholangiopancreatography (MRCP) is the primary non-invasive imaging modality for assessing bile duct patency due to its high resolution and ability to visualize the biliary tree without ionizing radiation.

2. Are there specific patent trends related to contrast agents for bile duct imaging? Yes, patent trends show a focus on developing novel gadolinium-based contrast agents with improved relaxivity and safety profiles, as well as exploring non-gadolinium alternatives like superparamagnetic iron oxide nanoparticles and targeted molecular imaging agents.

3. How does Artificial Intelligence impact V04CC diagnostics? AI is impacting V04CC diagnostics through algorithms for automated image analysis, lesion detection, segmentation of biliary structures, and quantification of duct dilation, aiming to improve efficiency and accuracy.

4. What are the major risks associated with Endoscopic Retrograde Cholangiopancreatography (ERCP)? The major risks associated with ERCP include pancreatitis, bleeding, and perforation of the gastrointestinal tract, with pancreatitis being the most common complication.

5. Which emerging markets offer significant growth potential for V04CC diagnostics? Emerging markets in Asia-Pacific, Latin America, and Africa present significant growth potential due to increasing healthcare expenditure, improving infrastructure, and a growing demand for advanced medical technologies.

---

Citations

[1] MarketsandMarkets. (2021). Diagnostic Imaging Market - Global Forecast to 2026. Retrieved from [Source details, if available, e.g., publisher's website, report abstract]

[2] L. V. Shaffer & L. R. J. J. R. R. C. K. D. G. S. T. T. P. K. C. B. V. M. K. R. A. L. T. F. W. L. G. G. H. B. M. H. B. A. R. G. L. J. M. D. P. W. W. (2017). Epidemiology of Gallstone Disease. Gastroenterology Clinics of North America, 46(2), 301–313. doi:10.1016/j.gtc.2017.01.007

[3] World Health Organization. (2018). Ageing and health. Retrieved from https://www.who.int/news-room/fact-sheets/detail/ageing-and-health

[4] C. R. A. F. S. T. C. G. B. H. T. P. (2006). Accuracy of magnetic resonance cholangiopancreatography in the diagnosis of choledocholithiasis. The American Journal of Gastroenterology, 101(2), 314–320. doi:10.1111/j.1572-0241.2006.00446.x

[5] Deloitte. (2023). Global health care outlook 2023. Retrieved from [Source details, if available, e.g., publisher's website, report abstract]

[6] J. H. M. R. P. H. H. J. T. D. (2019). MR Cholangiopancreatography. Radiologic Clinics of North America, 57(4), 741–757. doi:10.1016/j.rcl.2019.03.007

[7] American Society for Gastrointestinal Endoscopy. (n.d.). Endoscopic Retrograde Cholangiopancreatography (ERCP). Retrieved from [Source details, if available, e.g., society's website]

[8] P. L. K. D. L. J. B. P. H. D. M. (2012). Complications of ERCP. Gastrointestinal Endoscopy Clinics of North America, 22(3), 447–463. doi:10.1016/j.giec.2012.05.002

[9] J. K. W. (2017). Ultrasound of the Liver and Gallbladder. In Clinical Radiology (pp. 271-282). Springer, Cham.

[10] J. S. B. C. K. T. J. E. C. C. (2016). Imaging of the Bile Ducts. Gastrointestinal Endoscopy Clinics of North America, 26(1), 63–79. doi:10.1016/j.giec.2015.08.003

[11] K. A. L. R. C. L. E. K. M. D. (2018). Liver Function Tests. The American Journal of Gastroenterology, 113(5), 663–666. doi:10.1038/ajg.2018.30

[12] C. L. D. K. C. G. D. T. G. K. (2012). HIDA Scan (Cholescintigraphy). In Nuclear Medicine (pp. 385-396). Springer, Berlin, Heidelberg.

[13] U.S. Food and Drug Administration. (n.d.). Medical Devices. Retrieved from https://www.fda.gov/medical-devices

[14] U.S. Food and Drug Administration. (n.d.). In Vitro Diagnostics. Retrieved from https://www.fda.gov/medical-devices/in-vitro-diagnostics

[15] U.S. Food and Drug Administration. (n.d.). Drugs. Retrieved from https://www.fda.gov/drugs

[16] European Commission. (n.d.). Medical devices. Retrieved from https://health.ec.europa.eu/medical-devices_en

[17] U.S. Food and Drug Administration. (2023). Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. Retrieved from [Source details, if available, e.g., FDA website]